69
Participants
Start Date
January 9, 2018
Primary Completion Date
May 25, 2021
Study Completion Date
July 27, 2021
BI 655064
subcutaneous injection
Placebo
subcutaneous injection
Princess Alexandra Hospital, Woolloongabba
Mary Mediatrix Medical Center, Lipa City, Batangas
Southern Philippines Medical Center, Davao City
Columbia University Medical Center-New York Presbyterian Hospital, New York
Siriraj Hospital, Bangkok
King Chulalongkorn Memorial Hospital, Bangkok
Pramongkutklao Hospital, Rajathevee
Northwell Health, Great Neck
Feinstein Institute for Medical Research, Manhasset
General University Hospital, Prague
Institute of Rheumathology Prague, Prague
Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City
Instituto Nacional de Cs Médicas y Nutrición S Zubiran, Mexico City
Ajou University Hospital, Suwon
Centenario Hospital Miguel Hidalgo, Aguascalientes
NZOZ Centrum Medyczne AESKULAP,Private Prac, Radom, Radom
Integral Rheumatology and Immunology Specialist, Plantation
Hospital Tengku Ampuan Rahimah, Klang
Chiangmai University, Chiang Mai
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz
Robert-Bosch-Krankenhaus GmbH, Stuttgart
University General Hospital of Heraklion, Heraklion, Crete
Prince of Wales Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
CHU de Quebec-Universite Laval Research Centre, Québec
University General Hospital Attikon, Athens
Hokkaido University Hospital, Hokkaido, Sapporo
Tohoku University Hospital, Miyagi, Sendai
Okayama University Hospital, Okayama, Okayama
Juntendo University Hospital, Tokyo, Bunkyo-ku
University Clinical Hospital in Bialystok I, Bialystok
Norbert Barlicki University Clinical Hospital No.1, Lodz, Lodz
Hospital Curry Cabral, EPE, Lisbon
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital Santa Maria, Lisbon
Addenbrooke's Hospital, Cambridge
Guy's Hospital, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY